GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Current Deferred Revenue

Biosyent (TSXV:RX) Current Deferred Revenue : C$0.12 Mil (As of Mar. 2025)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Biosyent's current deferred revenue for the quarter that ended in Mar. 2025 was C$0.12 Mil.

Biosyent Current Deferred Revenue Historical Data

The historical data trend for Biosyent's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Current Deferred Revenue Chart

Biosyent Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 0.31 0.16 0.13 0.81

Biosyent Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.19 0.34 0.81 0.12

Biosyent Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Biosyent's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosyent Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Current Deferred Revenue
Comparable Companies
XCNQ:GRIN TSX:CRDL TSX:HLS TSXV:LOVE TSX:XLY TSX:TSND XCNQ:PLTH TSXV:SBBC TSX:MDP XCNQ:JUSH ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
BIOYF:USA
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Website
http://www.biosyent.com
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Executives
Peter Douglas Lockhard Director
Blair Driscoll 10% Security Holder
Merrilyn Joy Driscoll 10% Security Holder
Sean Driscoll 10% Security Holder
Fax Capital Corp. 10% Security Holder
Fax Investments Inc. 10% Security Holder
Federated Capital Corp. 10% Security Holder
Seyed Ahmad Ashrafi Director
Robert Joseph March Senior Officer
Sharan Raghubir Senior Officer
Rene Goehrum 10% Security Holder, Director, Senior Officer
Biosyent Inc. Issuer
Joost Van Der Mark Senior Officer
Sara Elford Director
Alfred D'souza Director

Biosyent Headlines

No Headlines